Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT07583563
Recruiting Observational

An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT07583563 · tracked via the Priya Life Science UK tracker
Sponsor
Camurus AB
Phase
Observational
Started
2026-06-05
Last updated
2026-10-27

Condition(s) studied

Acromegaly

Investigational drug(s) / intervention(s)

Octreotide subcutaneous depot

Octreotide subcutaneous depot: Commercially available octreotide subcutaneous depot treatment administered by participants for a maximum duration up to 2 years in the study

Study summary

The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Have started or will be starting treatment with octreotide SC depot for acromegaly Exclusion Criteria: * Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly * Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.

Primary outcome measure(s)

  • Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information. — From enrollment to the end of treatment at 2 years

Trial sites (7)

FacilityCityRegionStatus
Universitaetsklinikum Aachen Aachen Germany Recruiting
Universitaetsklinikum Leipzig Leipzig Germany Recruiting
Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie Magdeburg Germany Recruiting
Medicover Neuroendokrinologie MVZ München Germany Not Yet Recruiting
Universitätsklinikum Münster Münster Germany Not Yet Recruiting
Universitätsklinikum Würzburg Würzburg Germany Recruiting
St James's University Hospital - Leeds Teaching Hospitals NHS Trust Leeds United Kingdom Not Yet Recruiting

Other trials for the same condition

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07583563 on ClinicalTrials.gov ↗ ← All trials in the UK